| Rachel Ann Huffman, MD | |
|
125 E Cherry St, Bluffton, IN 46714-2002 | |
| (260) 919-3470 | |
| (260) 479-2980 |
| Full Name | Rachel Ann Huffman |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 125 E Cherry St, Bluffton, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164081535 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01084638A (Indiana) | Primary |
| Entity Name | Bluffton Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858879 PECOS PAC ID: 7618984253 Enrollment ID: O20060307000661 |
News Archive
American Indians living on reservations are at high risk for being exposed to such trauma as witnessing a loved one's death or being the victim of a physical attack, according to research comparing trauma on two American Indian reservations to that in the general U.S. population.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers in Iceland have published the largest ever studies of whole-genome data and effectively deduced the genetic code of "an entire nation."
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Ann Huffman, MD 6920 Pointe Inverness Way Ste 200, Fort Wayne, IN 46804-7934 Ph: (260) 479-3513 | Rachel Ann Huffman, MD 125 E Cherry St, Bluffton, IN 46714-2002 Ph: (260) 919-3470 |
News Archive
American Indians living on reservations are at high risk for being exposed to such trauma as witnessing a loved one's death or being the victim of a physical attack, according to research comparing trauma on two American Indian reservations to that in the general U.S. population.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers in Iceland have published the largest ever studies of whole-genome data and effectively deduced the genetic code of "an entire nation."
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.
› Verified 9 days ago
Baerbel H Stumpf, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 303 S Main St, Bluffton, IN 46714 Phone: 260-919-3470 Fax: 260-919-3556 | |
Dr. David C Brown, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 W Horton St, Bluffton, IN 46714 Phone: 260-824-0800 Fax: 260-824-7243 | |
Dr. Ma. Luisa S Sumabat, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 117 S Main St, Bluffton, IN 46714 Phone: 260-824-9265 Fax: 260-824-9267 | |
Dr. Lana K Patch, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 303 South Main Street, Bluffton, IN 46714 Phone: 260-919-3819 | |
Dr. George W Merkle, MD PC Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 360 N Main St, Ste A, Bluffton, IN 46714 Phone: 260-824-4315 Fax: 260-824-4962 | |
Dr. Michael Paul Volpe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 125 E Cherry St, Bluffton, IN 46714 Phone: 260-919-3470 Fax: 260-919-3556 |